Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda    crawled time : 11:00    save search
Todays' Top-5
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
Published: 2024-04-23 (Crawled : 11:00) - globenewswire.com
TLSA | News | $0.7501 -0.46% -0.47% 2.5M twitter stocktwits trandingview |
Health Technology
 | | O: 25.93% H: 4.71% C: -8.24%
fda life foralumab sclerosis sciences for program
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.24 0.0% 6.9M twitter stocktwits trandingview |
Health Technology
 | | O: 26.42% H: 3.48% C: -6.47%
ocu400 fda first clearance trial therapy
Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
HAE | $85.07 1.73% 0.0% 230K twitter stocktwits trandingview |
Health Technology
 | | O: 0.05% H: 1.54% C: 0.19%
teg fda clearance global
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
Published: 2024-03-20 (Crawled : 11:00) - globenewswire.com
CABA | $13.31 -0.08% -0.08% 760K twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 1.44% C: 0.67%
caba-201 fda drug granted sclerosis treatment designation
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
PEPG | $11.75 3.16% 3.06% 14K twitter stocktwits trandingview |
| | O: 1.94% H: 4.94% C: -2.9%
edo51 fda rare drug disease treatment duchenne
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
NRIX 6 d | $14.125 4.01% 3.86% 690K twitter stocktwits trandingview |
Health Technology
 | | O: 1.14% H: 4.19% C: -5.93%
nx-2127 fda trial therapeutics
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
LXRX | $1.62 -5.26% -5.56% 3.5M twitter stocktwits trandingview |
Health Technology
 | | O: 6.91% H: 21.55% C: 21.12%
fda diabetes
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
ADMA 4 | $6.535 5.4% 5.13% 2.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 0.0% C: -2.52%
bivigam fda
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.57% H: 0.0% C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K twitter stocktwits trandingview |
Health Technology
 | | O: 0.23% H: 0.9% C: -0.68%
praluent fda children genetic cholesterol approval treat injection
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
Published: 2024-02-23 (Crawled : 11:00) - prnewswire.com
BCLI A | $0.531 -1.69% -1.71% 170K twitter stocktwits trandingview |
Health Technology
 | | O: 8.93% H: 6.33% C: -3.06%
nurown fda als cell trial therapeutics
FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
Published: 2024-02-01 (Crawled : 11:00) - globenewswire.com
FENC M | $10.5 -3.05% -3.14% 100K twitter stocktwits trandingview |
Health Technology
 | | O: 0.6% H: 0.4% C: -0.6%
pedmark fda
GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia
Published: 2024-01-11 (Crawled : 11:00) - prnewswire.com
SLS | $1.615 4.87% 4.64% 2M twitter stocktwits trandingview |
Health Technology
 | | O: 1.84% H: 1.25% C: -4.34%
gfh009 fda drug t-cell granted lymphomas leukemia therapeutics
embecta Announces FDA 510(k) Submission for Insulin Patch Pump
Published: 2024-01-09 (Crawled : 11:00) - globenewswire.com
EMBC | $10.89 1.59% 1.56% 360K twitter stocktwits trandingview |
n/a
 | | O: -0.88% H: 0.47% C: -3.6%
fda insulin submission
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
Published: 2023-11-08 (Crawled : 11:00) - globenewswire.com
RTGN | $3.09 203.88% 400 twitter stocktwits trandingview |
n/a
 | Email alert Add to watchlist
fda drug device
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
Published: 2023-11-03 (Crawled : 11:00) - globenewswire.com
PSTV | News | $1.65 -0.6% -0.61% 17K twitter stocktwits trandingview |
Health Technology
 | | O: 9.56% H: 12.08% C: 7.38%
fda drug breast granted cancer treatment designation therapeutics plus
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
EYEN | $0.55 6.49% 6.09% 880K twitter stocktwits trandingview |
Health Technology
 | | O: 3.55% H: 8.9% C: -1.37%
fda mydcombi contract approval international commercial
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
SUPN | $29.98 0.91% 0.9% 200K twitter stocktwits trandingview |
Health Technology
 | | O: 1.38% H: 1.49% C: -0.7%
spn-830 fda device review
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Published: 2023-11-01 (Crawled : 11:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M twitter stocktwits trandingview |
Health Technology
 | | O: 0.83% H: 0.66% C: -0.68%
keytruda fda cancer treatment plus gemcitabine
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
Published: 2023-10-31 (Crawled : 11:00) - globenewswire.com
CRSP | News M | $56.46 1.44% 1.42% 1.2M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
fda crispr disease license review cell application therapeutics
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
Published: 2023-10-24 (Crawled : 11:00) - prnewswire.com
MIST | $1.67 2.45% 2.4% 90K twitter stocktwits trandingview |
Health Technology
 | | O: -1.54% H: 3.13% C: -1.17%
etripamil fda drug pharmaceuticals application milestone submission
Gainers vs Losers
78% 22%

Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M twitter stocktwits trandingview |

AGBA | $2.94 135.2% 57.48% 66M twitter stocktwits trandingview |
Finance
EDBL | News | $6.46 71.81% 41.8% 2M twitter stocktwits trandingview |

MTC | $2.25 44.23% 30.67% 6M twitter stocktwits trandingview |
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M twitter stocktwits trandingview |
Finance
SHIM | $3.05 35.56% 26.23% 1.1M twitter stocktwits trandingview |

HKIT | $1.345 31.86% 24.16% 390K twitter stocktwits trandingview |
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M twitter stocktwits trandingview |
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K twitter stocktwits trandingview |

POET | $1.59 27.2% 21.38% 4.2M twitter stocktwits trandingview |
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.